Lumify Preservative Free is a drug owned by Bausch And Lomb Inc. It is protected by 3 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 14, 2030. Details of Lumify Preservative Free's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9259425 | Compositions and methods for eye whitening |
Jul, 2030
(4 years from now) | Active |
| US8293742 | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(4 years from now) | Active |
| US11596600 | Vasoconstriction compositions and methods of use |
Jul, 2029
(3 years from now) | Active |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets
invalidated somehow, the
generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal
pitfalls. Given
below are details of the litigation history of Lumify Preservative Free and ongoing
litigations to
help you estimate the early arrival of Lumify Preservative Free generic.
Lumify Preservative Free's Litigations
Lumify Preservative Free been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 04, 2021, against patent number US9259425. The petitioner Slayback Pharma LLC, challenged the validity of this patent, with Eye Therapies, LLC as the respondent. Click below to track the latest information on how companies are challenging Lumify Preservative Free's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11596600 | February, 2024 | Pending | Eye Therapies, LLC et al. | Dr. Reddy's Laboratories S.A. et al. |
| US8293742 | November, 2021 |
Terminated-Settled
(13 Aug, 2025) | Eye Therapies, LLC et al. | Slayback Pharma LLC et al. |
| US11596600 | February, 2024 |
Terminated-Settled
(22 Jul, 2025) | Eye Therapies, LLC et al. | Dr. Reddy's Laboratories S.A. et al. |
| US11596600 | February, 2024 |
Trial Instituted
(10 Sep, 2024) | Eye Therapies, LLC et al. | Dr. Reddy's Laboratories S.A. et al. |
| US8293742 | November, 2021 |
Final Written Decision - Appealed
(15 May, 2023) | Eye Therapies, LLC et al. | Slayback Pharma LLC et al. |
| US9259425 | November, 2021 |
Terminated-Settled
(05 Oct, 2022) | Eye Therapies, LLC | Slayback Pharma LLC |
US patents provide insights into the exclusivity only within the United States, but
Lumify Preservative Free is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Lumify Preservative Free's family patents as well as insights into
ongoing legal events
on those patents.
Lumify Preservative Free's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lumify Preservative Free's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 14, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lumify Preservative Free Generic API suppliers:
Brimonidine Tartrate is the generic name for the brand Lumify Preservative Free. 13 different companies have already filed for the generic of Lumify Preservative Free, with Sandoz having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lumify Preservative Free's generic
Alternative Brands for Lumify Preservative Free
There are several other brand drugs in the same treatment category and using the same active ingredient (Brimonidine Tartrate) as Lumify Preservative Free. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Bausch And Lomb Inc |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Brimonidine Tartrate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Abbvie |
| ||
| Alcon Labs Inc |
| ||
| Galderma Labs Lp |
| ||
| Sandoz |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Brimonidine Tartrate, Lumify Preservative Free's active ingredient. Check the complete list of approved generic manufacturers for Lumify Preservative Free
About Lumify Preservative Free
Lumify Preservative Free is a drug owned by Bausch And Lomb Inc. Lumify Preservative Free uses Brimonidine Tartrate as an active ingredient. Lumify Preservative Free was launched by Bausch And Lomb Inc in 2024.
Approval Date:
Lumify Preservative Free was approved by FDA for market use on 19 April, 2024.
Active Ingredient:
Lumify Preservative Free uses Brimonidine Tartrate as the active ingredient. Check out other Drugs and Companies using Brimonidine Tartrate ingredient
Dosage:
Lumify Preservative Free is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.025% | SOLUTION/DROPS | Over the counter | OPHTHALMIC |